Ji Yun Jung

Ji Yun Jung

Auto-generated profile, based on publicly available information

Ji Yun Jung

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Clinical Neurology
Verified
Journal Article
Open access
SKSu-Hyun Kim
Su-Hyun Kim
YKYeseul Kim
Yeseul Kim
JJJi Yun Jung
Ji Yun Jung
NPNa-Young Park
Na-Young Park
HJHyunmin Jang
Hyunmin Jang
HKHo Jin Kim
Ho Jin Kim
Background and Purpose The anti-John-Cunningham virus (JCV)-antibody serostatus and index are used in the risk stratification of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with natalizumab. However, little information on these parameters is available for Asian countries. The purpose of this study was to determine the rate of seropositivity, index, and longitudinal index evolution in Korean patients with MS. Methods The antibody seroprevalence was analyzed in 355 samples from 187 patients with clinically isolated syndrome or MS using a second-generation, two-step, enzyme-linked immunosorbent assay. A 4-year longitudinal evaluation was applied to 66 patients. Results The overall antibody seroprevalence was 80% (n=149). Among antibody-positive patients, the index had a median value of 3.27 (interquartile range, 1.52-4.18), with 77% (n=114) and 56% (n=83) of patients having indices >1.5 and >3.0, respectively. The serostatus of 59 (89%) of the 66 patients did not change during the longitudinal analysis, while 3 (6%) of the 53 patients who were initially seropositive reverted to seronegativity, and 2 (15%) of the 13 patients who were initially seronegative converted to seropositivity. All patients with a baseline index >0.9 maintained seropositivity, and 92% of patients with a baseline index >1.5 maintained this index over 4 years. No patients developed PML (median disease duration, 8 years). Conclusions The seroprevalence and index of anti-JCV antibodies in Korean patients with MS may be higher than those in Western countries.